Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved ...

The FDA has expanded indications for two targeted combination treatments, Alyftrek and Trikafta, that will now benefit more ...

Vertex Pharmaceuticals stock is a "Strong Buy", driven by robust CF franchise growth and successful label expansions for ...

Vertex Pharmaceuticals (VRTX) announced on Wednesday that the U.S. FDA approved label expansions for Alyftrek and Trikafta, its treatments for cystic fibrosis, a hereditary disease caused by mutations ...

Agena Bioscience, a global provider of molecular genomics solutions, recently announced the launch of the CFTR 100+ Panel, a multiplex genotyping solution designed to provide expanded coverage of CFTR ...

- ALYFTREK ® (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene ...

Please provide your email address to receive an email when new articles are posted on . Sweat chloride values ranging from 30 mEq/L to 59 mEq/L were observed in “a surprisingly high proportion of ...

To clarify whether CFTR is a molecular target of intestinal fluid secretion caused by the anthraquinone compounds from laxative herbal plants. In the present study, we determined the potentiating ...

Please provide your email address to receive an email when new articles are posted on . Patients given aerosolized 4D-710 had elevated CFTR protein levels that went over normal levels. Over 12 months, ...

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1) ...

Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently.